Replimune Group (NASDAQ:REPL) Sees Strong Trading Volume

Replimune Group, Inc. (NASDAQ:REPL) saw unusually-high trading volume on Wednesday . Approximately 1,465,888 shares traded hands during trading, an increase of 31% from the previous session’s volume of 1,115,638 shares.The stock last traded at $11.46 and had previously closed at $11.90.

Wall Street Analyst Weigh In

REPL has been the subject of several recent research reports. HC Wainwright restated a “buy” rating and set a $17.00 target price on shares of Replimune Group in a research report on Monday, September 16th. Barclays upped their price objective on Replimune Group from $13.00 to $17.00 and gave the stock an “overweight” rating in a research note on Friday, June 7th. Roth Mkm initiated coverage on Replimune Group in a research report on Tuesday, August 27th. They set a “buy” rating and a $17.00 target price on the stock. JPMorgan Chase & Co. upped their price target on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 24th. Finally, Roth Capital raised Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $16.80.

Replimune Group Trading Up 0.8 %

The company has a quick ratio of 13.46, a current ratio of 13.46 and a debt-to-equity ratio of 0.16. The stock has a fifty day simple moving average of $10.40 and a 200 day simple moving average of $8.55. The firm has a market capitalization of $819.84 million, a P/E ratio of -3.67 and a beta of 1.22.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.10. As a group, research analysts forecast that Replimune Group, Inc. will post -3.11 EPS for the current year.

Insider Activity

In other news, CFO Emily Luisa Hill sold 8,938 shares of the stock in a transaction on Friday, August 16th. The shares were sold at an average price of $10.18, for a total value of $90,988.84. Following the sale, the chief financial officer now owns 101,057 shares of the company’s stock, valued at $1,028,760.26. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 20.60% of the company’s stock.

Institutional Trading of Replimune Group

A number of hedge funds and other institutional investors have recently bought and sold shares of REPL. Rafferty Asset Management LLC increased its holdings in Replimune Group by 148.1% during the fourth quarter. Rafferty Asset Management LLC now owns 463,397 shares of the company’s stock valued at $3,906,000 after buying an additional 276,596 shares during the period. Sectoral Asset Management Inc. raised its position in Replimune Group by 12.7% during the fourth quarter. Sectoral Asset Management Inc. now owns 305,412 shares of the company’s stock valued at $2,575,000 after acquiring an additional 34,356 shares in the last quarter. Pennant Investors LP acquired a new position in shares of Replimune Group in the 4th quarter valued at $257,000. Goldman Sachs Group Inc. increased its position in shares of Replimune Group by 300.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,238,883 shares of the company’s stock valued at $18,874,000 after buying an additional 1,679,553 shares in the last quarter. Finally, Fisher Asset Management LLC raised its position in shares of Replimune Group by 37.7% during the 4th quarter. Fisher Asset Management LLC now owns 77,663 shares of the company’s stock worth $655,000 after purchasing an additional 21,267 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.